Tucatinib for HER2-Positive Metastatic Breast Cancer: Eric P. Winer, MD

In this interview with i3 Health, Eric P. Winer, MD, discusses tucatinib (TukysaTM, Seattle Genetics), recently approved by the FDA in combination with trastuzumab and capecitabine for patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer previously treated with at least one anti-HER2­–based regimen in the metastatic setting. Dr. Winer, principal investigator of the phase 3 HER2CLIMB trial, on which the approval was based, discusses tucat...
Continue reading

Sacituzumab Govitecan for TNBC: An Interview With Sara Tolaney, MD, MPH

The FDA recently granted approval to sacituzumab govitecan-hziy (Trodelvy™, Immunomedics, Inc) for patients with metastatic triple-negative breast cancer (TNBC) who have received at least two prior therapies. Approval was based on a clinical trial (NCT01631552) that enrolled 108 patients with metastatic TNBC. In an interview with i3 Health, Sara Tolaney, MD, MPH, one of the study authors, provides insights on treating TNBC and the significance of the sacituzumab govitecan approval.What are the m...
Continue reading

Cancer Survivorship During COVID-19: Optimizing Care and Quality of Life

In the midst of the COVID-19 pandemic, cancer survivors face heightened physical and psychosocial challenges, as well as barriers to health care delivery. The authors of an editorial recently published in the Journal of Cancer Survivorship have provided specific suggestions as to how health care workers involved in cancer care can help to address cancer survivors' needs during this difficult time."The recent COVID-19 pandemic has affected the world and has the potential to disproportionately aff...
Continue reading

Expanding Later-Line Treatment Options for Multiple Myeloma: Paul G. Richardson, MD

Earlier this month, ​the FDA approved isatuximab-irfc (Sarclisa​®​, Sanofi), an anti-CD38 monoclonal antibody, in combination with pomalidomide and dexamethasone for adults with multiple myeloma who have received at least two prior lines of treatment, including lenalidomide and a proteasome inhibitor. In this interview with i3 Health, Paul G. Richardson, MD, who served as the co-primary investigator of the ICARIA-MM study, on which the isatuximab approval was based, shares his thoughts on the si...
Continue reading

Palbociclib for Early Breast Cancer

A phase 2 clinical trial assessing the feasibility of adjuvant palbociclib (Ibrance®, Pfizer) and endocrine therapy for patients with early breast cancer reports that it is an effective treatment for these patients.Palbociclib, a targeted therapy drug that inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), causes the cancerous cells to stop dividing and reproducing, ultimately stopping cancer growth. This drug has already been approved for advanced metastatic breast cancer. For the study, publi...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.